Compare Invesco NASDAQ 100 ETF (QQQM) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs 22nd Century Group Inc — how do they compare? Invesco NASDAQ 100 ETF trades at $290.86, while 22nd Century Group Inc trades at $4.2 (market cap $1.56M). The key difference: Invesco NASDAQ 100 ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| QQQM | XXII | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $307.23 | $999.00 |
52-Week Low | $228.02 | $3.90 |
Market Cap | — | $1.56M |
Enterprise Value | — | -$6.67M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $286.58 with minimal daily movement (+0.09%) amid bearish technical signals. The ETF faces headwinds from stretched tech valuations and rising AI competition, though recent Nasdaq-100 additions like SpaceX provide diversification. Technical indicators show oversold conditions with RSI at 22.39, while moving averages signal continued downward pressure.
The outlook remains cautious due to valuation concerns and sector rotation risks. However, the lower 0.15% expense ratio versus QQQ offers cost efficiency for long-term growth exposure. Key risks include AI market saturation and tech sector volatility, balanced by the fund's concentrated exposure to leading U.S. innovation companies.
XXII trades at $4.32, down 0.23% on the day, with neutral technical signals and bearish moving averages. The company shows significant financial challenges with negative profit margins (-65.76% net income margin) and declining revenue, though analyst sentiment remains positive with 75% buy ratings. Recent corporate actions include a 20:1 reverse stock split completed in June 2026, while expansion initiatives in California and New York aim to drive VLN brand growth.
The outlook remains speculative with high execution risk given persistent losses and negative ROE (-130.19%). Investment opportunity hinges on successful commercialization of reduced-nicotine products and FDA regulatory progress, but substantial financial deterioration and competitive pressures present significant downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
